SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): March 15, 2022
Cellectar Biosciences, Inc.
(Exact name of Registrant as Specified in its Charter)
|(State or other jurisdiction|
100 Campus Drive, Florham Park, NJ, 07932
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (608) 441-8120
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|¨||Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|¨||Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|¨||Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|¨||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
Securities registered pursuant to Section 12(b) of the Act:
|Title of each class||Trading|
|Name of each exchange|
on which registered
|Common Stock, par value $0.00001 per share||CLRB||The Nasdaq Capital Market|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
|Item 2.02.||Results of Operations and Financial Condition.|
As of December 31, 2021, Cellectar Biosciences, Inc., (the “Company”) had cash and cash equivalents of approximately $35.7 million (unaudited).
Because the Company’s consolidated financial statements for the year ended December 31, 2021 have not yet been finalized or audited, the preliminary statement of the Company’s cash and cash equivalents as of December 31, 2021 in this Item 2.02 is subject to change, and the Company’s actual cash and cash equivalents as of December 31, 2021 may differ materially from this preliminary estimate. Accordingly, you should not place undue reliance on this preliminary estimate.
|Item 7.01.||Regulation FD Disclosure.|
On March 16, 2022, the Company intends to make a presentation at the Oppenheimer 32nd Annual Healthcare Conference. This presentation would provide a Company overview, business update and progress on the Company’s key initiatives. A form of the Company's slide presentation to be used at this conference is being furnished as Exhibit 99.1 to this Current Report on Form 8-K, and a copy is available on the Company's website at investor.cellectar.com.
The information contained in Item 2.02 and Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is furnished pursuant to Item 2.02 and Item 7.01 of Form 8-K and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as expressly stated by specific reference in such filing.
|Item 9.01.||Financial Statements and Exhibits|
|104||Cover Page Interactive Data File (embedded within the Inline XBRL Document)|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|CELLECTAR BIOSCIENCES, INC.|
|Date: March 15, 2022||By:|
/s/ Chad J. Kolean
|Name:||Chad J. Kolean|
|Title:||Chief Financial Officer|